-
![CRYSTALLINE FORMS OF 3-Z-[1-(4-(N-((4-METHYL-PIPERAZIN-1-YL)-METHYLCARBONYL)-N-METHYL-AMINO)-PHENYLAMINO)-1-PHENYL-METHYLENE]-6-METHOXYCARBONYL-2-INDOLINONE](/abs-image/US/2020/01/02/US20200002294A1/abs.jpg.150x150.jpg)
公开(公告)号：US20200002294A1
公开(公告)日：2020-01-02
申请号：US16570710
申请日：2019-09-13
发明人： Fei LIU , Cuixia ZHANG , Weiming JIANG , Chin-Yu LAI , Tan NGUYEN , Haolong ZHANG
IPC分类号： C07D241/04 , A61K9/00
摘要： Crystalline forms of free base 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-phenylamino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone and preparation methods thereof are provided; the pharmaceutical formulations containing the crystalline forms and their use in the treatment of diseases, particularly angiogenic eye diseases are also provided.
-
公开(公告)号：US20200181214A1
公开(公告)日：2020-06-11
申请号：US16803561
申请日：2020-02-27
发明人： Pei-tzu WU , Jia-Hau SHIU , Madhu CHERUKURY , Tan NGUYEN , Kevin ZEN
摘要： The present invention relates to a biologic that inhibits angiogenesis. In particular, the present invention relates to fusion proteins that inhibit the integrin activated pathway and one other angiogenic factor-activated pathway, the compositions of these fusion proteins, as well as methods for producing and using the same.
-
公开(公告)号：US20220280506A1
公开(公告)日：2022-09-08
申请号：US17750400
申请日：2022-05-23
发明人： Tan NGUYEN , Chin-yu LAI
IPC分类号： A61K31/496 , A61K31/506 , A61K9/00 , A61K31/44 , A61K31/4439 , A61K9/51 , A61K47/38 , A61K9/10 , A61K9/14
摘要： Ophthalmic formulations containing nintedanib, or a pharmaceutically acceptable salt thereof are provided. The ophthalmic formulations can contain microparticles or nanoparticles of nintedanib. Also provided are methods of using the ophthalmic formulations for treating ocular surface diseases, such as dry eye disease.
-
公开(公告)号：US20190194271A1
公开(公告)日：2019-06-27
申请号：US16282786
申请日：2019-02-22
发明人： Pei-Tzu WU , Jia-Hau SHIU , Madhu CHERUKURY , Tan NGUYEN , Kevin Zen
CPC分类号： C07K14/46 , A61K38/00 , A61P9/10 , C07K14/71 , C07K2319/00 , C07K2319/02 , C07K2319/30
摘要： The present invention relates to a biologic that inhibits angiogenesis. In particular, the present invention relates to fusion proteins that inhibit the integrin activated pathway and one other angiogenic factor-activated pathway, the compositions of these fusion proteins, as well as methods for producing and using the same.
-
5.发明申请公开(公告)号：US20180243294A1
公开(公告)日：2018-08-30
申请号：US15964235
申请日：2018-04-27
发明人： Tan NGUYEN , Chin-yu LAI
IPC分类号： A61K31/496 , A61K9/00 , A61K31/4439 , A61K9/14
CPC分类号： A61K31/496 , A61K9/0048 , A61K9/10 , A61K9/146 , A61K9/5146 , A61K31/44 , A61K31/4439 , A61K31/506 , A61K47/38
摘要： Ophthalmic formulations containing nintedanib, or a pharmaceutically acceptable salt thereof are provided. The ophthalmic formulations can contain microparticles or nanoparticles of nintedanib. Also provided are methods of using the ophthalmic formulations for treating ocular surface diseases, such as dry eye disease.
-
公开(公告)号：US20180170979A1
公开(公告)日：2018-06-21
申请号：US15739089
申请日：2016-06-24
发明人： Pei-Tzu WU , Jia-Hau SHIU , Madhu CHERUKURY , Tan NGUYEN , Kevin ZEN
CPC分类号： C07K14/46 , A61K38/00 , A61P9/10 , C07K14/71 , C07K2319/00 , C07K2319/02 , C07K2319/30
摘要： The present invention relates to a biologic that inhibits angiogenesis. In particular, the present invention relates to fusion proteins that inhibit the integrin activated pathway and one other angiogenic factor-activated pathway, the compositions of these fusion proteins, as well as methods for producing and using the same.
-
7.发明申请公开(公告)号：US20170368061A1
公开(公告)日：2017-12-28
申请号：US15700735
申请日：2017-09-11
发明人： Tan NGUYEN , Chin-yu LAI
IPC分类号： A61K31/496 , A61K9/00 , A61K9/14 , A61K31/4439
CPC分类号： A61K31/496 , A61K9/0048 , A61K9/146 , A61K31/44 , A61K31/4439 , A61K31/506
摘要： Ophthalmic formulations containing tyrosine kinase inhibitors, such as Nintedanib, Axitinib, Sorafenib, and Pazopanib are described. The ophthalmic formulations can contain microparticles or nanoparticles of the tyrosine kinase inhibitor. Also described are methods of using the ophthalmic formulations for treating ocular surface diseases, such pterygium, including recurrent pterygium, and hyperemia associated with pterygium.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.018 秒)
